Protect inmates and staff at your facility with QuantiFERON-TB Gold Plus

Inmates and staff in correctional facilities are at an increased risk for TB infection. The best way to prevent TB transmission in these facilities is to identify latent TB infection (LTBI) and treat it before it poses a threat.


On-demand webinar: combating TB through modern control methods

Join Dr. Masae Kawamura as she discusses tuberculosis testing and prevention in corrections. You’ll learn about diagnostic tools for TB infection and new preventative treatment regimens that are increasing compliance and decreasing cost. Through case studies and publications, you’ll learn why the CDC recommends modern TB blood tests and how they can streamline testing at your facility.


Resource center: learn why accurate TB testing is critical for corrections

Prison inmates are more likely to present risk factors for TB – including HIV, homelessness, and substance abuse. The USPSTF now calls for latent TB testing for all adults in congregate settings, including correctional facilities (1).

Testing with TB blood tests and applying new shorter course treatment regimens improves screening and prevention program efficiency, effectiveness and costs.

To learn more about latent TB testing corrections, visit our corrections resource center. You’ll find downloadable resources on:

  • Combating tuberculosis in correctional facilities
  • Keeping inmates and employees healthy
  • Understanding modern TB control

Streamline TB testing with QuantiFERON-TB Gold Plus

QuantiFERON-TB Gold testing was introduced in New York City jails in 2011, replacing tuberculin skin testing (TST) which had been associated with substantial incomplete screening rates. In a published study of 35,090 persons, Katyal et al. reported that QFT testing in NYC jails yielded 6.3% positive, 93.4% negative, and 0.2% indeterminate results – and concluded that IGRA-based testing should be recommended in correctional settings (3).

In a separate 2016 study of 351 subjects tested with both QFT and the TB skin test at a Texas jail, Nijhawan et al. reported that the cost per LTBI case detected was nearly three times higher for TST than QFT-GIT ($1247 v $460; 4).

We found a substantially higher rate of QFT-GIT positivity compared to TST…  QFT-GIT as an initial screening tool was more time-efficient, and had four-fold fewer labor costs.



Modernize staff and inmate screening with QFT-Plus

Accurate

  • Unaffected by prior BCG vaccination
  • >97% specificity, >94% sensitivity

Convenient

  • Single patient visit
  • Single tube collection option

Cost-effective

  • Improves screening efficiency and reduces program costs (3)

Find out more about QFT-Plus at our Provider Resources Portal

References

1. Bibbins-Domingo, K. (2016) Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. Sep 6, 2016.
2. CDC. Tuberculosis in the United States, 2016. https://www.cdc.gov/tb/statistics/reports/2016/pdfs/2016_Surveillance_FullReport.pdf
3. Katyal et al., 2018; IGRA-Based Screening for Latent Tuberculosis Infection in Persons Newly Incarcerated in New York City Jails. Journal of Correctional Healthcare.
4. Nijhawan, A., et al. (2016) Cost analysis of tuberculin skin test and the QuantiFERON-TB Gold In-tube test for tuberculosis screening in a correctional setting in Dallas, Texas, USA. BMC Infect. Dis. 16, 564

Disclaimer: The performance of the USA format of the QFT-Plus test has not been extensively evaluated with specimens from individuals who have impaired or altered immune functions, such as those who have HIV infection or AIDS, those who have transplantation managed with immunosuppressive treatment or others who receive immunosuppressive drugs (e.g., corticosteroids, methotrexate, azathioprine, cancer chemotherapy), those who have other clinical conditions, such as diabetes, silicosis, chronic renal failure, and hematological disorders (e.g., leukemia and lymphomas), or those with other specific malignancies (e.g., carcinoma of the head or neck and lung).

Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Get in touch with QIAGEN
Follow QIAGEN on: